Cellares pushes back after BMS ends cell therapy manufacturing deal
Cellares is disputing Bristol Myers Squibb's characterization of its cell therapy manufacturing technology after the drugmaker terminated a contract. The startup says the technology meets standards, pushing back against BMS's claims. The partnership's conclusion has prompted a public rebuttal from Cellares.
Related stories
BMS scraps cell therapy manufacturing agreement, Cellares to restructure · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “Cellares rebukes Bristol Myers' criticism of its cell therapy technology.” Browse more stories.